Hence then, the article about innovent announces primary endpoint met in the phase 3 clinical trial restore 1 of ibi311 anti igf 1r antibody in treating thyroid eye disease and plans to submit nda to the nmpa was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA )
Also on site :
- The White Sox Have Decisions To Make With Munetaka Murakami
- Anthropic says engineering missteps were behind Claude Code’s monthlong decline after weeks of user backlash
- Largest catch-up initiative delivers over 100 million childhood vaccinations